This article was originally published in The Gray Sheet
Secondary offering of 3 mil. shares is planned at an estimated price of $14.50 per share. The Hayward, California firm, which produces the Cholestech L(D(X point-of-care analyte diagnostic system for multiple blood-detected diseases and disorders, plans to use anticipated net proceeds of approximately $40.4 mil. for expansion of manufacturing capacity in fiscal 1999, R&D expenses, "expansion of sales and marketing capabilities," other capital expenditures and working capital, and SG&A, the SEC filing states. Cholestech recorded sales of $21.7 mil. for the fiscal year ended March 27, 1998 (up 68%); earnings increased to roughly $2 mil. in its first year of profitability. Lead underwriter Prudential Securities and co-managers Vector Securities International and Everen Securities hold an over-allotment option for 450,000 shares, which could bring net proceeds to $46.5 mil
You may also be interested in...
The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.